Financial OutlookAnalyst reiterates a Buy rating while raising the 12-month price target to $30 from the prior $26 per share.
Product DevelopmentSepterna announced the selection of SEP-479 as its next-generation, oral PTH1R agonist candidate, which demonstrated robust, dose-dependent increases in serum calcium and decreases in endogenous parathyroid hormone levels in preclinical studies.
Strategic PartnershipsSepterna's partnership with Novo Nordisk A/S includes a $195M upfront payment and coverage of all R&D costs under the terms of the agreement.